Many patients keep using PPIs after negative GERD test

Many patients keep using PPIs after negative GERD test
Nearly half of patients continue to use proton pump inhibitors (PPIs) even after pH studies confirm that they do not have gastroesophageal reflux disease, and most do not recall being instructed to stop taking PPIs, according to a study published in the June issue of Clinical Gastroenterology and Hepatology.

(HealthDay) -- Nearly half of patients continue to use proton pump inhibitors (PPIs) even after pH studies confirm that they do not have gastroesophageal reflux disease (GERD), and most do not recall being instructed to stop taking PPIs, according to a study published in the June issue of Clinical Gastroenterology and Hepatology.

Andrew J. Gawron, M.D., of the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues conducted a retrospective study involving 90 patients who had undergone Bravo pH monitoring or multichannel intraluminal impedance-pH testing without evidence of GERD. Patients were compared by current use of PPIs.

The researchers found that 42.2 percent of patients continued to use PPIs despite a negative pH study result. Only 18.9 percent of patients remembered being instructed to stop taking PPIs. A chart review revealed documented instructions to stop PPI therapy in 16.7 percent of patients. Although no significant demographic or clinical differences were observed among patients currently taking PPIs or not, patients who continued to take a PPI were more likely to report troublesome symptoms that affected their daily life.

"Our findings suggest that a large proportion of patients with negative results from pH monitoring studies continue PPI therapy despite evidence contradicting the presence of GERD," the authors write. "In addition, most patients did not recall being counseled to stop their PPI, and such counsel was not documented in the majority of patients' medical records."

Two authors disclosed to the pharmaceutical and medical device industries.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

New hope for rare disease drug development

8 hours ago

Using combinations of well-known approved drugs has for the first time been shown to be potentially safe in treating a rare disease, according to the results of a clinical trial published in the open access Orphanet Journal of ...

Three weeks since last Ebola case in Mali: WHO

11 hours ago

Mali has not had a case of Ebola for three weeks, the World Health Organization said Wednesday, completing one of the two incubation periods the country needs to be declared free of the virus.

Migraine may double risk for facial paralysis

12 hours ago

Migraine headache may double the risk of a nervous system condition that causes facial paralysis, called Bell's palsy, according to a new study published in the December 17, 2014, online issue of Neurology, the medical journa ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.